CongoTuberculosis profile
Population  2014 4.5 million
Estimates of TB burden * 2014 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 2.1 (1.5–2.8) 46 (32–61)
Mortality (HIV+TB only) 2.5 (2.1–3) 55 (46–66)
Prevalence  (includes HIV+TB) 21 (11–33) 461 (255–728)
Incidence  (includes HIV+TB) 17 (15–19) 381 (335–430)
Incidence (HIV+TB only) 5.5 (4.3–6.9) 122 (96–152)
         
Case detection, all forms (%) 58 (52–66)    
Estimates of MDR-TB burden * 2014   New   Retreatment
% of TB cases with MDR-TB 2.2 (0.3–4.1) 11 (6.2–16)
MDR-TB cases among notified pulmonary
TB cases
160 (22–300) 41 (23–59)
TB case notifications 2014 New ** Relapse
Pulmonary, bacteriologically confirmed 3 876   196
Pulmonary, clinically diagnosed 3 479    
Extrapulmonary 2 466    
       
Total new and relapse 10 017    
Previously treated, excluding relapses 177    
Total cases notified 10 194    
Among 3 876 new cases:
103 (3%) cases aged under 15 years; male:female ratio: 1.5
Reported cases of RR-/MDR-TB 2014 New Retreatment Total **
Cases tested for RR-/MDR-TB   477 (128%) 477
Laboratory-confirmed RR-/MDR-TB cases     24
Patients started on MDR-TB treatment ***     0
TB/HIV 2014 Number (%)
TB patients with known HIV status 1 313 (13)
HIV-positive TB patients 386 (29)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 104 (27)
HIV-positive TB patients on antiretroviral therapy (ART) 94 (24)
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Treatment success rate and cohort size (%) Cohort
New cases registered in 2013    
Previously treated cases registered in 2013    
HIV-positive TB cases, all types, registered in 2013    
RR-/MDR-TB cases started on second-line treatment in 2012    
XDR-TB cases started on second-line treatment in 2012    
Laboratories 2014  
Smear (per 100 000 population) 0.7
Culture (per 5 million population) 0
Drug susceptibility testing (per 5 million population) 0
Sites performing Xpert MTB/RIF 1
Is second-line drug susceptibility testing available? No
Financing TB control 2015  
National TB programme budget (US$ millions) 1.1
% Funded domestically 99%
% Funded internationally 1%
% Unfunded 0%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
*** Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having
RR-/MDR-TB
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-05-01 Data: www.who.int/tb/data